Form 4: HCAT Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Health Catalyst Director Julie Larson-Green reported the sale of 47,997 shares of common stock at $2.6741 per share, executed under a pre-arranged 10b5-1 trading plan.
Summary
- Director Julie Larson-Green of Health Catalyst, Inc. (HCAT) reported a transaction involving the sale of common stock.
- The transaction occurred on December 4, 2025, and was filed with the SEC on December 8, 2025.
- A total of 47,997 shares of common stock were disposed of at a price of $2.6741 per share.
- This sale was executed pursuant to a Rule 10b5-1 trading plan, indicating it was pre-arranged.
- Following this transaction, Julie Larson-Green directly holds 73,573 shares of Health Catalyst, Inc. common stock.
Sentiment
Score: 4
Explanation: The sale of shares by a director, even under a pre-arranged 10b5-1 plan, can be perceived as a negative signal by investors, potentially indicating that the insider believes the stock is fully valued or that they need to diversify their holdings.
Negatives
- A director selling a significant number of shares (47,997 shares) could be perceived negatively by the market, potentially signaling a lack of confidence, even if pre-planned.
Future Outlook
No specific future outlook or guidance is provided in this insider transaction report.
Industry Context
This filing is an individual insider transaction report and does not provide broader industry context or trends.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | Director Julie Larson-Green executed a sale of shares under a Rule 10b5-1 trading plan, indicating a pre-arranged, non-discretionary transaction. | 12/04/2025 | Enhances transparency regarding insider stock transactions and provides an affirmative defense against insider trading allegations, but the sale itself may still be viewed negatively by the market. |
Stakeholder Impact
- Shareholders: May interpret the director's sale as a negative signal, potentially impacting stock price sentiment.
Key Dates
| Date | Description |
|---|---|
| 12/04/2025 | Transaction Date: Sale of 47,997 shares of common stock by Director Julie Larson-Green. |
| 12/08/2025 | Filing Date of Form 4 with the SEC. |
Recommendation
holdWhile the sale of shares by a director can be a negative signal, the transaction was executed under a pre-arranged 10b5-1 plan, which suggests it was not based on new, material non-public information. Investors should monitor future insider activity and broader company performance rather than making a definitive decision based solely on this single transaction.
Keywords
Health Catalyst, HCAT, Insider Trading, Form 4, Stock Sale, Director, Julie Larson-Green, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.